Lisinopril Dihydrate: Benchmark ACE Inhibitor for Hypertension Research

Executive Summary: Lisinopril dihydrate is a long-acting, orally active angiotensin converting enzyme (ACE) inhibitor, widely used in hypertension, heart failure, and renal disease research (https://www.apexbt.com/lisinopril-dihydrate.html). It exhibits a potent IC50 value of 4.7 nM against ACE, enabling effective inhibition of the renin-angiotensin system (Tieku & Hooper 1992). The compound’s water solubility (≥2.46 mg/mL) and high purity (≥98%) facilitate reproducible workflows. Lisinopril dihydrate is supplied by APExBIO as a validated research reagent. It is a lysine derivative of MK 421, providing mechanistic selectivity for ACE without significant inhibition of other peptidases (Tieku & Hooper 1992).

Biological Rationale

Angiotensin converting enzyme (ACE) is a zinc-dependent dipeptidyl carboxypeptidase (EC 3.4.15.1) responsible for converting angiotensin I to the vasoconstrictor angiotensin II (Tieku & Hooper 1992). Inhibition of ACE disrupts the renin-angiotensin system, a central regulator of blood pressure and fluid balance. Lisinopril dihydrate, a lysine analogue of MK 421, selectively inhibits ACE activity, reducing angiotensin II and aldosterone levels and increasing plasma renin (Related). This mechanism underpins its use in models of hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy (APExBIO).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate binds to the active site of ACE, chelating the catalytic zinc ion and blocking substrate access. The compound demonstrates an IC50 of 4.7 nM in cell-free assays with porcine kidney ACE at 25°C, pH 8.3 (Tieku & Hooper 1992). This inhibition is competitive and reversible. Lisinopril does not significantly inhibit related aminopeptidases (AP-N, AP-A, AP-W) at comparable concentrations, indicating high target selectivity. Physiologically, this blockade reduces angiotensin II-mediated vasoconstriction and aldosterone-driven sodium retention, leading to decreased blood pressure and afterload (See also).

Evidence & Benchmarks

• Lisinopril dihydrate has an IC50 value of 4.7 nM for ACE inhibition in vitro (Tieku & Hooper 1992, DOI).
• The compound is a lysine analogue of MK 421 and is structurally optimized for oral bioavailability and prolonged plasma half-life (APExBIO, product page).
• Lisinopril dihydrate does not significantly inhibit aminopeptidase N (AP-N), aminopeptidase A (AP-A), or aminopeptidase W (AP-W) at micromolar concentrations (Tieku & Hooper 1992, DOI).
• Solubility in water is ≥2.46 mg/mL with gentle warming and ultrasonication; the compound is insoluble in ethanol (APExBIO, B3290 kit).
• Purity is confirmed at ≥98% by mass spectrometry and NMR (APExBIO, product page).

Applications, Limits & Misconceptions

Lisinopril dihydrate is extensively used in preclinical models of hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy. Its selectivity enables precise interrogation of the renin-angiotensin system pathway. For example, it is used to benchmark ACE inhibition in murine, rat, and human tissue studies (Mechanistic Insight). In contrast to older ACE inhibitors, lisinopril dihydrate displays minimal off-target peptidase inhibition (Tieku & Hooper 1992).

Common Pitfalls or Misconceptions

• Not effective for non-ACE-mediated hypertension: Lisinopril dihydrate does not lower blood pressure in models where hypertension arises from mechanisms independent of the renin-angiotensin system.
• No inhibition of AP-N, AP-A, or AP-W: The compound is not a general peptidase inhibitor and does not affect aminopeptidase N, A, or W at pharmacologically relevant doses (Tieku & Hooper 1992).
• Insoluble in ethanol: Preparation in organic solvents such as ethanol is not recommended due to insolubility (APExBIO, spec sheet).
• Not stable in aqueous solution for long-term storage: Solutions should be freshly prepared, as prolonged storage can lead to degradation.
• Not a direct anti-inflammatory or anti-metastatic agent: The primary effect is on blood pressure regulation, not direct modulation of inflammation or metastasis.

For a more detailed exploration of advanced protocols and troubleshooting, see this article, which offers practical workflow integration strategies beyond the present mechanistic summary.

Workflow Integration & Parameters

Lisinopril dihydrate is provided as a solid powder with a molecular weight of 441.52 g/mol and chemical formula C21H35N3O7. For experimental use, dissolve in water (≥2.46 mg/mL) with gentle warming (≤37°C) and ultrasonic treatment if needed (APExBIO). Store dry powder desiccated at room temperature; avoid repeated freeze-thaw or long-term storage of solutions. Use freshly prepared solutions for in vitro or in vivo applications. Shipping is on blue ice to maintain compound integrity. For workflow optimization and troubleshooting, researchers are advised to review advanced application notes (Advanced Applications), which detail protocol adaptations and troubleshooting for diverse preclinical models. This article expands on those workflows by providing a comparative mechanistic context and explicit physicochemical details.

Conclusion & Outlook

Lisinopril dihydrate is a validated, high-purity, long-acting ACE inhibitor with robust selectivity and workflow compatibility. It remains a cornerstone for studies targeting the renin-angiotensin system in cardiovascular and renal research. With detailed product characterization and mechanistic clarity, B3290 from APExBIO facilitates reproducible, high-impact experimentation. For further mechanistic insight and translational guidance, consult this reference, which situates lisinopril dihydrate within a broader experimental landscape, complementing the specific data presented here.